This research aims to bridge the gap between genomics and clinical prac4ce in breast cancer

by:

Developing a clinical decision support system (CDSS): Integra4ng genomic data with clinical
informa4on to predict pa4ent response and recommend personalized treatment op4ons.
Refining pa4ent stra4fica4on: Crea4ng more accurate risk assessment models for beEer
predic4on of disease progression and treatment response.
Iden4fying novel therapeu4c targets: Discovering ac4onable muta4ons that can be targeted
with exis4ng or emerging therapies.

Expected Contribu0ons:

Advancement of Breast Cancer Classifica4on: Our research is poised to contribute to a

refined classifica4on of breast cancer based on genomic characteris4cs, moving beyond
tradi4onal subtypes to enable more targeted and precise treatment strategies.

Clinical Guidelines for Genomic Integra4on: The study aims to provide insights into the
development of guidelines for the integra4on of genomic informa4on into rou4ne clinical
prac4ce. This includes recommenda4ons for gene4c tes4ng, interpreta4on of results, and
treatment decision-making.

Enhanced Treatment Efficacy: By iden4fying specific gene4c markers associated with

treatment responses, our research has the poten4al to enhance treatment efficacy, minimize
adverse effects, and improve overall pa4ent outcomes.

Contribu4on to Precision Medicine Paradigm: Ul4mately, this research seeks to contribute to

the broader paradigm shiS towards precision medicine in breast cancer care, emphasizing
the importance of tailoring interven4ons to the unique gene4c makeup of each pa4ent.

Future Direc0ons:

Integra4on of new technologies: Explore incorpora4ng liquid biopsy and circula4ng tumor
DNA analysis for real-4me monitoring of treatment response.
Expanding applicability: Adapt and modify the CDSS for other cancer types with established
genomic drivers.
Advocacy and policy engagement: Promote wider adop4on of precision medicine prac4ces
within healthcare systems.

Conclusion:
This research demonstrates significant progress in bridging the gap between genomics and
clinical prac4ce in breast cancer. The developed tools and insights hold immense poten4al
for personalized treatment, improved pa4ent outcomes, and ul4mately, a future where
precision medicine becomes the standard of care for breast cancer pa4ents.